Johnson & Johnson (JNJ)

JNJ (NYSE:Drugs)
$101.22
pos +0.86
+0.86%
Today's Range: 100.52 - 101.79 | JNJ Avg Daily Volume: 7,227,100
Last Update: 10/22/14 - 4:00 PM EDT
Volume: 9,359,401
YTD Performance: 9.58%
Open: $101.10
Previous Close: $100.36
52 Week Range: $86.09 - $108.77
Oustanding Shares: 2,820,287,326
Market Cap: 279,772,502,739
6-Month Chart
TheStreet Ratings Grade for JNJ
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 5 5 4 4
Moderate Buy 3 3 3 3
Hold 8 8 8 8
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.19 2.19 2.27 2.27
Latest Dividend: 0.70
Latest Dividend Yield: 2.82%
Dividend Ex-Date: 11/21/14
Price Earnings Ratio: 18.97
Price Earnings Comparisons:
JNJ Sector Avg. S&P 500
18.97 16.40 27.46
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-0.90% 10.04% 57.35%
GROWTH 12 Mo 3 Yr CAGR
Revenue 6.10 0.16 0.05
Net Income 31.50 0.04 0.01
EPS 24.60 0.01 0.00
Earnings for JNJ:
EBITDA 23.06B
Revenue 71.31B
Average Earnings Estimates
Qtr (12/14) Qtr (03/15) FY (12/14) FY (12/15)
Average Estimate $1.25 $1.52 $5.96 $6.19
Number of Analysts 9 5 11 14
High Estimate $1.29 $1.61 $6.00 $6.45
Low Estimate $1.21 $1.39 $5.91 $5.99
Prior Year $1.24 $1.54 $5.52 $5.96
Growth Rate (Year over Year) 1.08% -1.04% 7.94% 3.91%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Jim Cramer

 | Oct 21, 2014 | 1:28 PM EDT

Welcome back to the airlines and the biotechs.

By

David Katz

 | Oct 21, 2014 | 12:30 PM EDT

Investing during a mid-term election can offer large returns.

By

David Katz

 | Oct 17, 2014 | 10:00 AM EDT

There is a disconnect between stock prices and intrinsic value.

bearishJohnson & Johnson numbers lowered at BofA/Merrill

Oct 15, 2014 | 8:36 AM EDT

Shares of JNJ now seen reaching $99, according to Bank of America/Merrill Lynch. Estimates also cut, as the company is facing multiple growth headwinds. Neutral rating. 

By

Jim Cramer

 | Oct 14, 2014 | 3:43 PM EDT

It doesn't stop even as some of these pullbacks are irrational.

By

David Katz

 | Oct 14, 2014 | 12:30 PM EDT

There may be a wave of consolidation.

By

Jim Cramer

 | Oct 14, 2014 | 10:55 AM EDT

Because it's completely hit or miss.

By

Jim Cramer

 | Oct 1, 2014 | 2:18 PM EDT

I am disappointed by the lack of scoops and against-the-grain research.

By

Dick Arms

 | Sep 30, 2014 | 7:00 AM EDT

Overbought levels suggest decline is headed lower.

bullishJohnson & Johnson rated new Outperform at BMO

Sep 5, 2014 | 8:12 AM EDT

JNJ was initiated with an Outperform rating, BMO Capital said. $118 price target. Company is a market leader and can expand into emerging markets.

The major market indices continue to move within the parameters of the Fibonacci retraceme...
Since we cleared a key decision on the way up, I want to watch this pullback for an entry ...
Conclusion DDD is down today on new that the firm has cut revenue forecast due to producti...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.